A detailed history of Aviva PLC transactions in Biogen Inc. stock. As of the latest transaction made, Aviva PLC holds 18,532 shares of BIIB stock, worth $2.76 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
18,532
Previous 18,274 1.41%
Holding current value
$2.76 Million
Previous $4.24 Million 15.2%
% of portfolio
0.01%
Previous 0.01%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$189.07 - $236.8 $48,780 - $61,094
258 Added 1.41%
18,532 $3.59 Million
Q2 2024

Aug 02, 2024

SELL
$190.52 - $236.72 $2.64 Million - $3.28 Million
-13,849 Reduced 43.11%
18,274 $4.24 Million
Q1 2024

May 14, 2024

SELL
$212.02 - $267.71 $7.39 Million - $9.33 Million
-34,836 Reduced 52.03%
32,123 $6.93 Million
Q4 2023

Feb 09, 2024

BUY
$222.59 - $267.94 $3.96 Million - $4.76 Million
17,770 Added 36.13%
66,959 $17.3 Million
Q3 2023

Nov 13, 2023

SELL
$253.3 - $285.89 $2.04 Million - $2.31 Million
-8,072 Reduced 14.1%
49,189 $12.6 Million
Q2 2023

Aug 10, 2023

BUY
$275.25 - $318.06 $6.74 Million - $7.79 Million
24,493 Added 74.75%
57,261 $16.3 Million
Q1 2023

May 12, 2023

SELL
$256.56 - $292.34 $3.41 Million - $3.89 Million
-13,292 Reduced 28.86%
32,768 $9.11 Million
Q4 2022

Feb 09, 2023

BUY
$252.44 - $306.72 $6.09 Million - $7.4 Million
24,112 Added 109.86%
46,060 $12.8 Million
Q3 2022

Nov 14, 2022

SELL
$194.69 - $268.46 $610,937 - $842,427
-3,138 Reduced 12.51%
21,948 $5.86 Million
Q2 2022

Aug 04, 2022

SELL
$187.54 - $223.02 $2.3 Million - $2.74 Million
-12,283 Reduced 32.87%
25,086 $5.12 Million
Q1 2022

May 13, 2022

SELL
$193.77 - $244.14 $1.69 Million - $2.13 Million
-8,733 Reduced 18.94%
37,369 $7.87 Million
Q4 2021

Feb 10, 2022

SELL
$223.92 - $287.77 $789,765 - $1.01 Million
-3,527 Reduced 7.11%
46,102 $11.1 Million
Q3 2021

Nov 12, 2021

BUY
$282.99 - $369.05 $302,516 - $394,514
1,069 Added 2.2%
49,629 $14 Million
Q2 2021

Aug 10, 2021

SELL
$259.0 - $414.71 $523,957 - $838,958
-2,023 Reduced 4.0%
48,560 $16.8 Million
Q1 2021

May 13, 2021

SELL
$242.95 - $284.63 $391,149 - $458,254
-1,610 Reduced 3.08%
50,583 $14.2 Million
Q4 2020

Feb 10, 2021

BUY
$236.26 - $355.63 $280,676 - $422,488
1,188 Added 2.33%
52,193 $12.8 Million
Q3 2020

Nov 12, 2020

SELL
$264.77 - $305.71 $848,058 - $979,189
-3,203 Reduced 5.91%
51,005 $14.5 Million
Q2 2020

Aug 13, 2020

SELL
$258.66 - $342.55 $1.78 Million - $2.36 Million
-6,890 Reduced 11.28%
54,208 $14.5 Million
Q1 2020

May 14, 2020

SELL
$268.85 - $341.04 $736,111 - $933,767
-2,738 Reduced 4.29%
61,098 $19.3 Million
Q4 2019

Feb 10, 2020

SELL
$220.06 - $304.07 $253,729 - $350,592
-1,153 Reduced 1.77%
63,836 $18.9 Million
Q3 2019

Nov 12, 2019

SELL
$217.44 - $243.88 $1.55 Million - $1.74 Million
-7,132 Reduced 9.89%
64,989 $15.1 Million
Q2 2019

Jul 30, 2019

SELL
$219.29 - $241.72 $512,480 - $564,899
-2,337 Reduced 3.14%
72,121 $16.9 Million
Q1 2019

May 14, 2019

SELL
$216.71 - $338.96 $339,584 - $531,150
-1,567 Reduced 2.06%
74,458 $17.6 Million
Q4 2018

Feb 12, 2019

SELL
$278.5 - $352.75 $5.99 Million - $7.59 Million
-21,516 Reduced 22.06%
76,025 $22.9 Million
Q3 2018

Nov 13, 2018

SELL
$293.51 - $383.83 $2.63 Million - $3.44 Million
-8,962 Reduced 8.41%
97,541 $34.5 Million
Q2 2018

Aug 01, 2018

SELL
$257.52 - $306.91 $357,695 - $426,297
-1,389 Reduced 1.29%
106,503 $30.9 Million
Q1 2018

May 14, 2018

SELL
$260.13 - $367.91 $2.63 Million - $3.71 Million
-10,095 Reduced 8.56%
107,892 $29.5 Million
Q4 2017

Feb 13, 2018

SELL
$307.64 - $344.58 $5.34 Million - $5.99 Million
-17,373 Reduced 12.83%
117,987 $37.6 Million
Q3 2017

Nov 13, 2017

BUY
$281.15 - $329.69 $185,558 - $217,595
660 Added 0.49%
135,360 $42.4 Million
Q2 2017

Aug 07, 2017

BUY
N/A
134,700
134,700 $36.5 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.5B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Aviva PLC Portfolio

Follow Aviva PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aviva PLC, based on Form 13F filings with the SEC.

News

Stay updated on Aviva PLC with notifications on news.